Artificial Intelligence
Kraken Reports Q2 2021 Results
ST. JOHN’S, Newfoundland and Labrador, Aug. 26, 2021 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (TSX-V: PNG, OTCQB: KRKNF), Canada’s Ocean Company, announced it has filed its financial results for the quarter ended June 30, 2021. Additional information concerning the Company, including its consolidated financial statements and related management’s discussion and analysis (“MD&A”) for the quarter ended June 30, 2021, can be found at www.sedar.com. Unless otherwise stated, all dollar amounts are Canadian dollar denominated.
2021 Financial Guidance
- Revenue for the year ended December 31, 2021 is expected to be $28 million to $30 million, an increase of more than 130% as compared to $12 million in 2020. The forecasted growth is driven by initial deliveries of KATFISH™ 180 towed sonars and Autonomous Launch and Recovery Systems for the Danish and Polish navies and various orders for AquaPix® MINSAS sensors and SeaPower™ batteries. In addition, our revenue guidance includes the forecasted five months of contribution from the acquisition of PanGeo, which closed on July 30, 2021.
- Gross margins for 2021 are expected to be in the 47%-50% range versus 47% in 2020.
- Adjusted EBITDA* for 2021 is expected to be in the range of $3.0 million to $4.5 million compared to an Adjusted EBITDA* loss of $2.7 million in 2020. The year over year improvement is expected as a result of higher revenue offset by increased expenses on headcount and infrastructure related spending, and overall costs due to the growth of the business.
- Net income for 2021 is expected to range from a net loss of $1.0 million to net income of $1.5 million. This compares to a net loss of $5.5 million in 2020.
- Over the last 12 months, Kraken has purchased significant inventory to de-risk delivery schedules that could be negatively impacted by the COVID 19 pandemic’s impact on supply chains. The Company continues to pre-buy long lead-time inventory for current 2021 and planned 2022 deliveries, with a primary focus being on electronic integrated circuits. With the ongoing efforts of our engineering and procurement teams to expedite parts orders, we are continuing to mitigate inventory supply risks.
*Adjusted EBITDA and Adjusted EBITDA margin do not have standardized meaning under IFRS and may not be comparable to similar measures used by other issuers. We define Adjusted EBITDA as revenue less costs of sales, administrative expenses, research and development costs plus investment tax credits. We define Adjusted EBITDA margin as Adjusted EBITDA divided by revenues.
Q2 2021 Financial Highlights
- Revenue for the quarter was $1.9 million compared to $2.3 million in the year ago quarter. Revenue in the quarter related mainly to progress on the Danish Navy order.
- Adjusted EBITDA* in the quarter was negative $0.2 million, compared to Adjusted EBITDA* of $0.4 million in the year ago quarter.
- Net loss in the quarter was $0.9 million compared to $0.1 million in the year ago quarter.
- Net working capital at the end of Q2, 2021 was $5.2 million, compared to $10.9 million at the end of 2020. Kraken exited the quarter with a cash and restricted cash of $5.4 million, compared to $13.9 million at December 31, 2020. The main driver of the reduction in cash over the last 12 months has been a planned increase in inventory builds ($7 million inventory increase since Q2, 2020) to address potential supply chain challenges (as noted above) and prepare for the start of significant deliveries in the second half of 2021.
- Including federal funding we will receive for our OceanVision project, at quarter end Kraken had $7.1 million in previously awarded funding to draw upon from government agencies and project funding partners. This amount is not recorded in our financial statements until the cash is received.
Q2 2021 Corporate Developments
During the quarter, Kraken:
- Closed the acquisition of 13 Robotics Ltda of Brazil (“13R”). The 13R team, with offices in Rio de Janeiro and Salvador, Brazil, consists of software developers and engineers who have significant experience in underwater robotics and autonomous systems for the energy markets. Kraken will utilize their expertise in robotic system development, leverage their relationships with leading international energy companies, and have a base of opportunity for Robotics/Data as a Service capabilities in South America.
- Joined LifeMoor mooring chain inspection project and industry collaboration. In conjunction with Kraken becoming a new member of LifeMoor, Kraken has entered into a project agreement with a major East Coast offshore energy operator. The project objective is to validate SeaVision® Mooring Chain Inspection Tool (MCIT) on a mooring chain provided by the offshore energy operator and to integrate SeaVision® MCIT with LifeMoor analytics software.
- Signed a CRADA on pressure tolerant batteries with the US Navy. Kraken will be testing its batteries with Naval Surface Warfare Center Carderock, which has significant experience with US Navy safety requirements. Kraken believes this will help increase adoption of Kraken’s pressure tolerant batteries into US Navy programs of record and sales with US Navy defense contractors.
- Signed a cooperation agreement with SH Defense of Denmark on containerized subsea surveillance payloads for the naval and commercial marine industry. These modular payloads will include Kraken surveillance systems and SH container modules. SH Defense will globally promote and sell containerized subsea surveillance solutions with a variety of Kraken’s surveillance solutions. In Canada, Kraken, supported by SHD, will promote, sell, deliver, install and service SHD hydraulic, electric and mechanical system modular containerized solutions to the Royal Canadian Navy, Canadian Coast Guard and commercial industry.
Subsequent Events
- In July, Kraken signed a contract with a major international energy company to provide detailed underwater inspection of the customer’s subsea assets. Kraken’s SeaVision® 3D laser scanner will be used to conduct underwater inspection of an umbilical termination assembly to acquire metrology data on tubing within the internal structure. The work will be performed in Q4 of this year in a West African country.
- In July, Kraken was awarded a $0.6 million Robotics as a Service (RaaS) contract from Newfoundland and Labrador Hydro (formerly Nalcor Energy) for the Underwater Inspection of Strait of Bell Isle Submarine Cable. Under the contract, Kraken will deploy its KATFISH™ towed SAS sonar system including our Automatic/Remote Launch and Recovery System (ALARS) deployed on the R/V Ocean Seeker. This contract will be executed in Q3, 2021.
- On July 26, Kraken completed a $10 million bought deal equity financing.
- On July 30, Kraken completed the acquisition of PanGeo. Together with PanGeo, Kraken can now offer a holistic solution of world-leading technologies and services in subsea acoustic and optical imaging, autonomous robotics, and subsea batteries for customers in the defense and commercial markets.
- On August 11, PanGeo announced the award of $2.0 million in cash funding from Canada’s Ocean Supercluster for PanGeo’s Geoscan project. The Geoscan project will focus on reconfiguring PanGeo’s Acoustic Corer™ 3D technology to allow for a wider area scan and the ability to image geohazards to depths greater than 30 meters sub-seabed. In addition to providing wider area scans, PanGeo will incorporate new Artificial Intelligence (AI) processing technology to improve data acquisition and accelerate data processing. Ultimately this technology will lead to a reduction of personnel offshore and improved vessel efficiencies.
LINKS
www.krakenrobotics.com
www.pangeosubsea.com
SOCIAL MEDIA
LinkedIn www.linkedin.com/company/krakenrobotics
Twitter www.twitter.com/krakenrobotics
Facebook www.facebook.com/krakenroboticsinc
YouTube www.youtube.com/channel/UCEMyaMQnneTeIr71HYgrT2A
Instagram www.instagram.com/krakenrobotics
ABOUT KRAKEN ROBOTICS INC.
Kraken Robotics Inc. (TSX.V:PNG) (OTCQB: KRKNF) is a marine technology company dedicated to the production and sale of software-centric sensors, subsea batteries and thrusters, and underwater robotic systems. The company is headquartered in Newfoundland with offices in Canada, U.S., Germany, Denmark, and Brazil. In July 2021, Kraken acquired PanGeo Subsea, a leading services company specializing in high-resolution 3D acoustic imaging solutions for the sub-seabed. PanGeo with offices in Canada, the United States and the United Kingdom is now a wholly owned subsidiary of Kraken. Kraken is ranked as a Top 100 marine technology company by Marine Technology Reporter.
Certain information in this news release constitutes forward-looking statements. When used in this news release, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “seek”, “propose”, “estimate”, “expect”, and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. In particular, this news release contains forward-looking statements with respect to, among other things, business objectives, expected growth, results of operations, performance, business projects and opportunities and financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such statements reflect the Company’s current views with respect to future events based on certain material factors and assumptions and are subject to certain risks and uncertainties, including without limitation, changes in market, competition, governmental or regulatory developments, general economic conditions and other factors set out in the Company’s public disclosure documents. Many factors could cause the Company’s actual results, performance or achievements to vary from those described in this news release, including without limitation those listed above. These factors should not be construed as exhaustive. Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may vary materially from those described in this news release and such forward-looking statements included in, or incorporated by reference in this news release, should not be unduly relied upon. Such statements speak only as of the date of this news release. The Company does not intend, and does not assume any obligation, to update these forward-looking statements. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange Inc. nor its Regulation Services Provide (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release, and the OTCQB has neither approved nor disapproved the contents of this press release.
For further information, please contact:
Joe MacKay, Chief Financial Officer
(416) 303-0605
[email protected]
Greg Reid, Chief Operating Officer
(416) 818-9822
[email protected]
Sean Peasgood, Investor Relations
(647) 955-1274
[email protected]
STOCKHOLM, April 19, 2024 /PRNewswire/ — On 5 April 2024, SciBase Holding AB (publ) (“SciBase” or the “Company”) announced that the Board of Directors, with the support of the authorization granted by the annual general meeting held on 17 May 2023, had resolved on a rights issue of units, consisting of new shares and warrants of series TO 2, of approximately SEK 15 million (the “Rights Issue). Today, SciBase announces that the prospectus relating to the Rights Issue (the “Prospectus”) has been approved by the Swedish Financial Supervisory Authority (the “SFSA”) and has been made available on the Company’s webpage, https://investors.scibase.se/en/share/prospectus-regarding-shares, together with other information related to the Rights Issue. The Prospectus will also be made available on Vator Securities’ webpage, www.vatorsecurities.se , and at the SFAS’s webpage, www.fi.se.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.
Timetable for the Rights Issue
19 April 2024
Record date to receive unit rights
23 April 2024 – 2 May 2024
Trading in unit rights
23 April 2024 – 7 May 2024
Subscription period
23 April 2024 – 27 May 2024
Trading in BTU
Around 10 May 2024
Announcement of the outcome of the Rights Issue
3 April 2029 – 17 April 2029
Subscription period for warrants of series TO 2
Advisors
Vator Securities is the financial advisor and Advokatfirman Schjødt is the legal advisor to SciBase in connection with the Rights Issue.
For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA)Vator SecuritiesTel: +46 8 580 065 99Email: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The Company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
Important information
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Any acquisition of units in SciBase in the Rights Issue should only be made on the basis of the information contained in the formal prospectus issued in connection with the Rights Issue, which was approved by the Swedish Financial Supervisory Authority on 19 April 2024.
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“Securities Act”) and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
This press release contains forward-looking statements related to the Company’s intentions, estimates or expectations with regard to the Company’s future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “implies,” “should,” “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue,c3964524
The following files are available for download:
https://mb.cision.com/Main/12371/3964524/2745667.pdf
Publishing of prospectus SciBase
View original content:https://www.prnewswire.co.uk/news-releases/scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue-302122089.html
Artificial Intelligence
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 – Exclusive Report by 360iResearch
PUNE, India, April 18, 2024 /PRNewswire/ — The report titled “Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $342.20 million in 2023 to reach $832.56 million by 2030, at a CAGR of 13.54% over the forecast period.
“The Global Surge in Adoption of Matching Software for Enhanced Participant Enrollment”
Clinical trials matching software stands at the forefront of revolutionizing clinical research by automating the process of identifying and enrolling eligible participants. These platforms offer a streamlined approach to match patient health profiles with trial requirements, accelerating enrollment and supporting the shift toward personalized healthcare using these advanced AI and ML technologies. Although integrating these systems poses challenges due to variations in healthcare IT infrastructure and the imperative for rigorous data security, the potential for market growth is substantial. In the Americas, a robust clinical trials ecosystem thrives; in the European Union, it has unified regulatory standards and extended to emerging regions such as the Middle East, Africa, and the APAC countries; the demand for such innovative solutions is on a steep rise. This demand is fueled by governmental support, the evolving regulatory landscape, and strategic partnerships to embed these solutions within electronic health records, underscoring a global movement toward optimizing clinical trial processes to better cater to specific patient demographics.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“The Rise of Virtual Trials and Advanced Matching Software”
The healthcare landscape is witnessing a transformative shift toward virtual clinical trials, fueled by technological advancements and the necessity for continuity during the COVID-19 pandemic. This transition supports research amid social distancing measures and introduces significant cost savings by reducing the need for physical infrastructure and in-person interactions. The efficiencies brought by electronic health records (EHR), wearable technologies, and automation streamline the entire process, from patient recruitment to data analysis. Several approaches, endorsed by regulatory bodies such as the FDA, represent a leap forward in making clinical trials more accessible and streamlined, ensuring that more patients can participate in potentially life-saving research without the geographical and logistic constraints of traditional trials.
“Enhancing Clinical Trials through Advanced Analytics, Rigorous Compliance, and Precision-Patient Matching”
Integrating advanced analytics, meticulous compliance monitoring, and precision-patient matching marks a significant advancement toward maximizing efficiency and fostering trial diversity. The software delivers insightful data on trial progress, participant demographics, and enrollment figures, empowering stakeholders to make well-informed decisions and optimize resource distribution to meet trial goals effectively by implementing cutting-edge analytics. The built-in compliance feature ensures trials are conducted in strict adherence to regulatory standards, minimizing risks associated with non-compliance. Furthermore, a robust data management system guarantees the integrity and availability of clinical trial data, which is critical for the seamless operation and real-time analysis of trials. The software includes state-of-the-art patient matching technology, which employs sophisticated algorithms and artificial intelligence to expedite recruitment by accurately identifying candidates who match specific trial requirements. This innovative approach accelerates the recruitment timeline and enhances the diversification of trial participants, paving the way for more inclusive and representative clinical research outcomes.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Medidata by Dassault Systèmes SE at the Forefront of Clinical Trials Matching Software Market with a Strong 11.30% Market Share”
The key players in the Clinical Trials Matching Software Market include International Business Machines Corporation, Science 37, Inc. by eMed, LLC, Medidata by Dassault Systèmes SE, AutoCruitment LLC, Deep 6 AI Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trials Matching Software Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trials Matching Software Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trials Matching Software Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Dive into the Clinical Trials Matching Software Market Landscape: Explore 190 Pages of Insights, 286 Tables, and 22 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trials Matching Software Market, by FunctionalityClinical Trials Matching Software Market, by DeploymentClinical Trials Matching Software Market, by End-UseAmericas Clinical Trials Matching Software MarketAsia-Pacific Clinical Trials Matching Software MarketEurope, Middle East & Africa Clinical Trials Matching Software MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030Virtual Clinical Trials Market – Global Forecast 2024-2030Clinical Trials Management System Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo – https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clinical-trials-matching-software-market-projected-to-reach-832-56-million-by-2030—exclusive-report-by-360iresearch-302119709.html
BOSTON, April 18, 2024 /PRNewswire/ — The RepTrak™ Company, the world’s leading reputation data and insights company, released its annual Global RepTrak 100 report. Utilizing its advanced reputation monitoring software, RepTrak gathered data from more than 243,000 survey responses across 14 major economies to rank the world’s 100 most reputable companies. They share that ranking alongside a full analysis of global corporate reputation trends and corresponding public sentiment in the 2024 report.
After two years of consecutive Reputation Score declines, this year’s Score is back up with an increase from 73.2 in 2023 to 73.8 in 2024. It’s a small increase after 2023’s full one-point drop. However, it’s an encouraging sign that companies have begun to recover from reputation falls driven by many challenges: macroeconomic issues, workplace difficulties, product problems, and corporate responsibility skepticism.
“This year’s report underscores a pivotal shift in the corporate landscape, spotlighting the remarkable adaptability and dedication of the Top 100 companies in responding to the dynamic needs of stakeholders,” states RepTrak CEO Mark Sonders. “The companies featured in our report are not just riding the wave of change; they are the ones steering it, proving that the best approach to business is one that embraces evolution and champions progress.”
RepTrak’s report explores how people thought, felt, and acted toward companies over the past year. Findings include notable increases in Conduct and Citizenship efforts, stakeholders’ rising willingness to invest, culturally resonant brand communications, and ESG Scores that soared despite skepticism around the acronym.
To read the full 2024 Global RepTrak 100 report, please visit: www.reptrak.com/globalreptrak
About RepTrak
The RepTrak™ Company is the world’s leading reputation data and insights company. We help companies by organizing and grading a variety of reputational elements, offering a real-world report card on their corporate reputation. Subscribers to the RepTrak program use our predictive insights to protect business value, improve return on investment, and increase their positive impact on society. RepTrak’s pairing of advanced metrics and dedicated reputation advisors offers clients an actionable analysis of their reputation data, aligning business objectives with stakeholder sentiment across different markets and sectors.
Established in 2004, The RepTrak Company owns the world’s largest reputation benchmarking database, gathering over 1 million company ratings per year used by CEOs, boards, and executives in more than 60 countries worldwide. For more information, please visit: www.reptrak.com
Logo – https://mma.prnewswire.com/media/2391550/RepTrak_Logo_Logo.jpg
Photo – https://mma.prnewswire.com/media/2391551/2024_GRT_Spreads__Instagram_Post.jpg
View original content:https://www.prnewswire.co.uk/news-releases/reptrak-announces-2024-global-reptrak-100-report-302121513.html
-
Artificial Intelligence7 days agoIn-Depth Analysis of Germany and France Data Center Markets: Germany Poised to Contribute Over $12.24 Billion Opportunities in the Next 6 Years – Arizton
-
Artificial Intelligence7 days agoCogX Festival Set to Debut in Los Angeles at Century Plaza on May 7th, 2024
-
Artificial Intelligence5 days agoSilent Eight secures AIA as its latest client
-
Artificial Intelligence4 days agoGlobal Networking Innovator Huawei Leads the New Era of Campus Network Technology
-
Artificial Intelligence4 days agoBroadcom Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Delivering Reliable and Flexible Hybrid Cloud Management Solutions
-
Artificial Intelligence2 days agoHuawei Introduces AI Technologies to Accelerate Network Transformation Towards All Intelligence in the Net5.5G Era
-
Artificial Intelligence4 days agoAI Chips and Chat GPT – IDTechEx Explores AI and Robotics
-
Artificial Intelligence4 days agoGFT teams up with Google Cloud to launch ‘GenAI Intelligent Assistant’
